Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions

Abstract

The use of SESs in the treatment of chronic total coronary occlusions is associated with a reduction in the rate of major adverse cardiac events and restenosis compared with BMS.

Comparison of Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusion Using Everolimus- Versus Sirolimus- Versus Paclitaxel-Eluting Stents (from the Korean National Registry of Chronic Total Occlusion Intervention)

“…16,17 However, comparison between different DESs in CTO intervention has not been well established. Furthermore, the efficacy of the EES for the treatment of CTOs remains unclear.…”

Therapie des chronischen Koronararterienverschlusses

“…Die Restenoserate lag selbst nach Einführung der Metall-Stents bei 30-50%, und v. a. die Reverschlussrate war mit bis zu 20% deutlich höher als bei nichtokklusiven Läsio-nen [33,34]. Mit Einsatz der DES wurde diese Rezidivrate signifikant gesenkt, was nicht nur verschiedene Register [35,36,37], sondern letztlich auch randomisierte Studien belegten ( [38,39,40]; . Abb.…”

Complex Angioplasty up to Chronic Total Occlusion*

“…Success rate for occlusions < 15 mm in length is 71% versus 58% for longer lesions [15]. Data on mid-and long-term outcome after successful CTO recanalization are summarized in Tables 1 (for percutaneous transluminal coronary angioplasty [PTCA] in the treatment of CTO), 2 (for utilizing BMS, as well as comparison of BMS vs. PTCA in the treatment of CTO) and 3 (for DES vs. BMS in the treatment of CTO) [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36]. The majority of studies reported greater mid-and long-term event-free survival in patients with successful CTO recanalization compared to unsuccessful CTO treatment [19-22, 27, 31, 32].…”

“…Based on decrease in restenosis and reocclusion rates after stent placement following successful CTO opening [23,24,26], stent implantation became a standard intervention in a recanalized CTO. Recent studies have documented superiority of DES over BMS for the treatment of CTO with better mid-term angiographic and clinical results, both for sirolimus-and paclitaxel-eluting stents [33][34][35][36].…”